Cost-effectiveness analysis of Human Papillomavirus (HPV) Vaccination in the Netherlands: Recent publication reinforces favorable cost-effectiveness despite misleading conclusion

Vaccine

Volumn 28, Issue 4, 2010, Pages 873-874

  Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Cost effectiveness; Discounting; HPV

Indexed keywords

WART VIRUS VACCINE;

COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; NETHERLANDS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; VACCINATION; VIRUS INFECTION; WART VIRUS;

COST-BENEFIT ANALYSIS; HUMANS; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 73949122501     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.109     Document Type: Editorial

References (16)

1. Rogoza R.M., Ferko N., Bentley J., Meijer C.J., Berkhof J., Wang K.-L., et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 26S (2008) F46-58
2. Rogoza R.M., Westra T.A., Ferko N., Tamminga H., Drummond M.F., Daemen T., et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 27 (2009) 4776-4783
3. De Kok I.M., van Ballegooijen M., and Habbema J.D. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 101 (2009) 1083-1092
4. http://www.ispor.com.
5. College voor Zorgverzekeringen (Health Care Insurance Board; CvZ). Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie (2006), CvZ, Diemen (the Netherlands) [in Dutch]
6. Gravelle H., and Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 10 (2001) 587-599
7. Klok R.M., Brouwer W.B.F., Annemans L.A., Bos J.M., and Postma M.J. Towards a healthier discount procedure. Expert Rev Pharmacoecon Outcomes Res 5 1 (2005) 59-63
8. Brouwer W.B.F., Niessen L.W., Postma M.J., and Rutten F.F.H. Need for differential discounting of costs and health effects in cost effectiveness analysis. Brit Med J 331 (2005) 446-448
9. Claxton K., Sculpher M., Culyer A., McCabe C., Briggs A., Akehurst R., et al. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. Health Econ 15 (2006) 1-4
10. Gravelle H., Brouwer W., Niessen L., Postma M., and Rutten F. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ 16 (2007) 307-317
11. http://www.cvz.nl.
12. Postma M.J. Public health economics of vaccines in the Netherlands: methodological issues and applications. J Public Health 16 (2008) 267-273
13. Ferko N., Postma M.J., Gallivan S., Kruzikas D., and Drummond M. Evolution of the economics of cervical cancer vaccination. Vaccine 26S (2008) F3-F15
14. Coupe V.M., van Ginkel J., de Melker H.E., Snijders P.J., Meijer C.J., and Berkhof J. HPV 16/18 vaccination to prevent cervical cancer in the Netherlands. Int J Cancer 124 (2009) 970-978
15. Raad voor Volksgezondheid & Zorg (RVZ). Rechtvaardige en duurzame zorg (2007), RVZ, Den Haag [in Dutch]
16. Gezondheidsraad (Health Council; GR). Vaccinatie tegen baarmoederhalskanker (2008), GR, The Hague (the Netherlands) [in Dutch]